Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2022 Feb 12;113(2):335–344. doi: 10.1016/j.ijrobp.2022.02.014

Table 2A.

Patient and Treatment Characteristics

No. of Patients (%)

Characteristic Radiation Resistance WT or VUS (n = 73) Radiation Resistance mt (n = 16) p – value

Age 0.006
 Median, Range (years) 68 (52 – 83) 64 (46 – 79)

Ever Smoker 0.104
 Yes 55 (75) 15 (94)

Sex 0.665
 Female 46 (63) 11 (69)
 Male 27 (37) 5 (31)

Performance Status 0.689
 ECOG 0 45 (62) 9 (56)
 ECOG 1 28 (38) 7 (44)

Histology 0.391
 Adenocarcinoma 65 (89) 13 (81)
 Other 8 (11) 3 (19)

Tumor Mutational Burden 0.163
 Median, IQR (mt/Mb) 6.1 (2.6–10.5) 10.5 (6.1–15.8)

AJCC 8th Overall Stage 0.672
 < III 7 (10) 1 (6)
 IIIA or IIIB 66 (90) 15 (94)

Margin Status 0.985
 Negative 64 (88) 14 (88)
 Positive 9 (12) 2 (12)

Involved Mediastinal Nodal Stations 0.158
 <2 54 (74) 9 (56)
 ≥2 19 (26) 7 (44)

Received Chemotherapy 0.116
 Yes 63 (86) 16 (100)

Received ICI 0.350
 Yes 11 (15) 1 (6)

Received TKI 0.113
 Yes 10 (14) 0

Radiation Dose 0.616
 Median, range (Gy) 54 (50 – 60) 54 (50.4 – 60)

Radiation Technique
 3D-CRT 15 (20) 3 (19) 0.871
 IMRT 58 (80) 13 (81)